{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:17:42Z","timestamp":1788322662848,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T00:00:00Z","timestamp":1520812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s11606-018-4383-0","type":"journal-article","created":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T15:36:51Z","timestamp":1520869011000},"page":"769-772","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A Case of Disseminated Histoplasmosis in a Patient with Rheumatoid Arthritis on Abatacept"],"prefix":"10.1007","volume":"33","author":[{"given":"Nina","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B.","family":"Doyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob E.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga-Marie","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie E.","family":"Johncilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agoston T.","family":"Agoston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj K.","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo E.","family":"Vel\u00e1squez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,12]]},"reference":[{"issue":"Suppl 5","key":"4383_CR1","doi-asserted-by":"publisher","first-page":"v38","DOI":"10.1093\/rheumatology\/kes114","volume":"51","author":"A Rubbert-Roth","year":"2012","unstructured":"Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford). 2012;51 Suppl 5:v38\u201347. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kes114\n                    \n                  .","journal-title":"Rheumatology (Oxford)"},{"key":"4383_CR2","unstructured":"Food and Drug Administration. Postmarket drug safety information for patients and providers\u2014information for healthcare professionals: Cimzia (certolizumab pegol), Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab). Available at: \n                    http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124185.htm\n                    \n                  . Accessed 7 Dec 2016."},{"issue":"1","key":"4383_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/annrheumdis-2013-203843","volume":"73","author":"M Schiff","year":"2014","unstructured":"Schiff M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73(1):86\u201394. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2013-203843\n                    \n                  .","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"4383_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1128\/CMR.00027-06","volume":"20","author":"CA Kauffman","year":"2007","unstructured":"Kauffman CA. Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev. 2007;20(1):115\u2013132. \n                    https:\/\/doi.org\/10.1128\/CMR.00027-06\n                    \n                  .","journal-title":"Clin Microbiol Rev."},{"issue":"11","key":"4383_CR5","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa050524","volume":"353","author":"MC Genovese","year":"2005","unstructured":"Genovese MC, Becker J-C, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor \u03b1 inhibition. N Engl J Med. 2005;353(11):1114\u20131123. \n                    https:\/\/doi.org\/10.1056\/NEJMoa050524\n                    \n                  .","journal-title":"N Engl J Med."},{"key":"4383_CR6","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1164\/ajrccm.150.1.8025760","volume":"150","author":"GP LeMense","year":"1994","unstructured":"LeMense GP, Sahn SA. Opportunistic infection during treatment with low dose methotrexate. Am J Respir Crit Care Med. 1994;150:258\u2013260.","journal-title":"Am J Respir Crit Care Med."},{"issue":"9990","key":"4383_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","volume":"386","author":"JA Singh","year":"2015","unstructured":"Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386(9990):258\u2013265. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(14)61704-9\n                    \n                  .","journal-title":"Lancet"},{"issue":"2","key":"4383_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2165\/00063030-200418020-00005","volume":"18","author":"LM Bang","year":"2004","unstructured":"Bang LM, Keating GM. A review of its use in rheumatoid arthritis. Biodrugs. 2004;18(2):121\u2013139.","journal-title":"Biodrugs."},{"issue":"1","key":"4383_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1086\/648724","volume":"50","author":"CA Hage","year":"2010","unstructured":"Hage CA, Bowyer S, Tarvin SE, Helper D, Kleiman MB, Wheat LJ. Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. Clin Infect Dis. 2010;50(1):85\u201392. \n                    https:\/\/doi.org\/10.1086\/648724\n                    \n                  .","journal-title":"Clin Infect Dis."},{"issue":"3","key":"4383_CR10","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/rheumatology\/keq287","volume":"50","author":"M Schiff","year":"2011","unstructured":"Schiff M. Abatacept treatment for rheumatoid arthritis. Rheumatology (Oxford). 2011;50(3):437\u2013449. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/keq287\n                    \n                  .","journal-title":"Rheumatology (Oxford)."},{"issue":"8","key":"4383_CR11","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1002\/art.21978","volume":"54","author":"WG Dixon","year":"2006","unstructured":"Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DPM. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti\u2013tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54(8):2368\u20132376. \n                    https:\/\/doi.org\/10.1002\/art.21978\n                    \n                  .","journal-title":"Arthritis Rheum."},{"issue":"1","key":"4383_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2007.083188","volume":"68","author":"C Salliot","year":"2009","unstructured":"Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis. 2009;68(1):25\u201332. \n                    https:\/\/doi.org\/10.1136\/ard.2007.083188\n                    \n                  .","journal-title":"Ann Rheum Dis."},{"key":"4383_CR13","unstructured":"FDA Approved Drug Products: BLA 125118. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125118s209lbl.pdf\n                    \n                  . Accessed 27 Dec 2017."},{"issue":"7","key":"4383_CR14","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1086\/521259","volume":"45","author":"LJ Wheat","year":"2007","unstructured":"Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the infectious diseases society of America. Clin Infect Dis. 2007;45(7):807\u2013825. \n                    https:\/\/doi.org\/10.1086\/521259\n                    \n                  .","journal-title":"Clin Infect Dis."},{"issue":"2","key":"4383_CR15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1469-0691.2007.01891.x","volume":"14","author":"B Denis","year":"2008","unstructured":"Denis B, Lefort A, Flipo RM, et al. Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-\u03b1 antagonist therapy: safe re-initiation of TNF-\u03b1 blockers after appropriate anti-tuberculous treatment. Clin Microbiol Infect. 2008;14(2):183\u2013186. \n                    https:\/\/doi.org\/10.1111\/j.1469-0691.2007.01891.x\n                    \n                  .","journal-title":"Clin Microbiol Infect."},{"issue":"1","key":"4383_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(1):1\u201326. \n                    https:\/\/doi.org\/10.1002\/art.39480\n                    \n                  .","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"4383_CR17","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/annrheumdis-2013-204011","volume":"74","author":"H Yun","year":"2015","unstructured":"Yun H, Xie F, Delzell E, et al. Risk of hospitalized infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. Ann Rheum Dis. 2015;74(6):1065\u20131071. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2013-204011\n                    \n                  .","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"4383_CR18","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3899\/jrheum.120906","volume":"40","author":"ME Weinblatt","year":"2013","unstructured":"Weinblatt ME, Moreland LW, Westhovens R, et al. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. J Rheumatol. 2013;40(6):787\u2013797. \n                    https:\/\/doi.org\/10.3899\/jrheum.120906\n                    \n                  .","journal-title":"J Rheumatol."},{"issue":"5","key":"4383_CR19","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/ard.62.5.423","volume":"62","author":"M Hoekstra","year":"2003","unstructured":"Hoekstra M, van Ede AE, Haagsma CJ, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62(5):423\u2013426. \n                    https:\/\/doi.org\/10.1136\/ard.62.5.423\n                    \n                  .","journal-title":"Ann Rheum Dis."},{"issue":"9258","key":"4383_CR20","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/S0140-6736(00)04172-6","volume":"357","author":"M Boscaro","year":"2001","unstructured":"Boscaro M, Barzon L, Fallo F, Sonino N. Cushing\u2019s syndrome. Lancet. 2001;357(9258):783\u2013791. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(00)04172-6\n                    \n                  .","journal-title":"Lancet."},{"issue":"2","key":"4383_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0002-9343(94)90131-7","volume":"96","author":"KG Saag","year":"1994","unstructured":"Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med. 1994;96(2):115\u2013123. \n                    https:\/\/doi.org\/10.1016\/0002-9343(94)90131-7\n                    \n                  .","journal-title":"Am J Med."},{"issue":"9","key":"4383_CR22","doi-asserted-by":"publisher","first-page":"705","DOI":"10.7326\/0003-4819-138-9-200305060-00006","volume":"138","author":"DJ Winston","year":"2003","unstructured":"Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial. Ann Intern Med. 2003;138(9):705. \n                    https:\/\/doi.org\/10.7326\/0003-4819-138-9-200305060-00006\n                    \n                  .","journal-title":"Ann Intern Med."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11606-018-4383-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-018-4383-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-018-4383-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T21:03:52Z","timestamp":1552338232000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11606-018-4383-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,12]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["4383"],"URL":"https:\/\/doi.org\/10.1007\/s11606-018-4383-0","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,12]]},"assertion":[{"value":"2 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors have no conflicts of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}